Veterinary Pain Management Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Medications, Medical Devices), By Application (Joint Pain, Cancer Pain, Postoperative Pain, Others), By Animal Type (Companion Animal, Livestock Animal), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.15 Billion
CAGR (2026-2031)	7.82%
Fastest Growing Segment	Companion Animal
Largest Market	North America
Market Size (2031)	USD 4.95 Billion

Market Overview

The Global Veterinary Pain Management Market is projected to grow from USD 3.15 Billion in 2025 to USD 4.95 Billion by 2031 at a 7.82% CAGR. The Global Veterinary Pain Management Market encompasses products and services dedicated to alleviating pain in animals, ranging from pharmaceuticals such as NSAIDs and opioids to therapeutic devices and complementary therapies. Market expansion is primarily driven by the increasing humanization of pets, leading to greater owner willingness to invest in advanced veterinary care, alongside a rising global pet population. According to the American Veterinary Medical Association, in 2025, pet owners spent approximately $1,700 per year per household on their pets, with veterinary care accounting for 32.4% of these expenditures.

Concurrently, an aging animal demographic and a higher incidence of chronic conditions like osteoarthritis contribute significantly to the demand for effective pain management solutions. A notable impediment to market growth, however, is the substantial cost associated with long-term pain management protocols, which can pose a financial burden for pet owners, particularly in regions with limited pet insurance penetration.

Key Market Drivers

The increased pet ownership and humanization of pets represents a pivotal driving factor for the Global Veterinary Pain Management Market, as owners increasingly view their animals as integral family members deserving of high-quality medical care. This shift in perception translates directly into a greater willingness to invest in advanced treatments and long-term wellness solutions, including those for pain relief. Pet owners are actively seeking therapies that enhance their companions' comfort and quality of life, fostering demand for a broader spectrum of pain management modalities, from pharmaceuticals to rehabilitative services. According to a MetLife Pet Insurance survey published in 2026, the average pet owner spent approximately $2,360 on their pet in 2025, demonstrating this elevated financial commitment. This growing emotional bond encourages proactive veterinary visits and adherence to comprehensive care plans, significantly expanding the market for veterinary pain management products and services.

Concurrently, the growing prevalence of acute and chronic animal diseases significantly contributes to the escalating demand for veterinary pain management solutions. As animals live longer due to improved nutrition and veterinary care, they are increasingly susceptible to age-related conditions, degenerative diseases, and various acute ailments that necessitate effective pain control. This includes conditions such as osteoarthritis, cancer, and other chronic inflammatory processes. For instance, a study published in March 2026 by researchers at the University of Tennessee College of Veterinary Medicine found that 60% of evaluated dogs aged four to ten years had radiographic evidence of osteoarthritis. Such high disease prevalence underscores the ongoing need for advanced diagnostic tools and therapeutic interventions to manage pain effectively. Overall, according to the American Pet Products Association's 2026 State of the Industry Report, total U.S. pet industry expenditures reached $158 billion in 2025, reflecting a robust and expanding market where pain management plays an essential role.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with long-term pain management protocols represents a significant impediment to the growth of the Global Veterinary Pain Management Market. This financial burden often compels pet owners to make difficult decisions regarding their pets' care, sometimes leading to the delay or complete foregoing of necessary treatments. This directly limits the uptake of advanced and sustained pain management solutions, even as the demand for such care increases due to an aging animal demographic and rising incidence of chronic conditions.

The reluctance to commit to expensive, ongoing care protocols actively constrains market expansion. According to the American Animal Hospital Association (AAHA), nearly half of pet owners reported that unexpected veterinary expenses caused financial concern in 2025, an increase from one in three in 2022. This demonstrates a tangible barrier where owners, despite emotional attachment, face economic realities that restrict their ability to invest in comprehensive pain management therapies. This financial strain thus slows the adoption of both pharmaceutical and therapeutic interventions.

Key Market Trends

A significant trend impacting the Global Veterinary Pain Management Market is the ongoing innovation in drug formulations and delivery systems, which aims to improve convenience and efficacy for both veterinarians and pet owners. These advancements frequently focus on creating longer-lasting pain relief options, thereby enhancing animal welfare by reducing the frequency of administration and improving compliance. For instance, Zoetis received European Commission marketing authorization in October 2025 for Portela (relfovetmab), an innovative monoclonal antibody therapy offering a three-month dosing interval for alleviating pain associated with osteoarthritis in cats. This development reflects a market shift towards solutions that provide extended pain control, leading to improved animal quality of life and potentially fostering stronger owner adherence to treatment protocols.

Concurrently, strategic investment in novel therapeutic technologies is shaping the market by expanding the scope of available pain management options beyond conventional pharmaceuticals. This trend encompasses the integration of diverse scientific approaches and external collaborations to develop breakthrough solutions for chronic conditions. As reported by Boehringer Ingelheim in its "Animal Health Partnering and Innovation Outlook 2026," the company aims to anchor 30% of its research and development pipeline in external innovation, a strategy that in 2025 included integrating novel therapeutic vaccine technology specifically to address unmet needs in chronic diseases such as pain. Such investments drive the diversification of treatment modalities, offering more targeted and advanced options for complex pain conditions in animals.

Segmental Insights

The Companion Animal segment is emerging as the fastest-growing sector within the Global Veterinary Pain Management Market. This rapid expansion is primarily driven by the increasing global trend of pet ownership and the growing humanization of companion animals, which prompts owners to invest more significantly in advanced veterinary healthcare and long-term wellness. Furthermore, a heightened awareness of animal welfare, coupled with the rising prevalence of age-related and chronic conditions such as osteoarthritis in an aging pet population, fuels the demand for effective pain management solutions. Advances in veterinary diagnostics and the continuous development of novel analgesic therapies further contribute to this segment's robust growth.

Regional Insights

North America holds the leading position in the global veterinary pain management market, primarily driven by its advanced veterinary healthcare infrastructure and extensive pet ownership rates. This dominance stems from substantial pet owner expenditure on veterinary services, fueled by a growing awareness of animal welfare and the critical need for effective pain management solutions. A stringent regulatory framework, supported by agencies such as the U.S. Food and Drug Administration (FDA) overseeing animal drug approvals, ensures product safety and effectiveness, thereby encouraging continuous innovation in therapeutic options. Furthermore, the region benefits from a significant presence of skilled veterinary professionals and key industry participants, which collectively bolsters its market leadership.

Recent Developments

• In April 2026, Gallant, an animal health biotechnology company, achieved eligibility for the FDA Center for Veterinary Medicine's expanded conditional approval pathway for its intravenous uterine-derived mesenchymal stromal cell therapy, intended for feline osteoarthritis. This designation offers an expedited route to market for therapies addressing critical unmet needs in veterinary medicine. Initial pilot clinical study findings indicated that more than 76% of treated cats experienced significant improvements in their quality of life over a 90-day period, marking a promising advancement in managing chronic pain for felines.
• In October 2025, Elanco Animal Health initiated a collaboration with the Senior Dog Veterinary Society, aiming to improve osteoarthritis (OA) pain management for older canines. This partnership facilitates educational events, discussions on innovative treatments, and certifications for veterinary professionals specializing in senior dog care, with a strong focus on OA. The initiative seeks to elevate awareness of OA pain indicators and equip pet owners to collaborate effectively with veterinarians on appropriate pain management strategies, reflecting Elanco's dedication to animal welfare.
• In April 2025, Creative Science, a CIMA Animal Health company, completed the acquisition of Astaria Global. Astaria Global is an equine health company recognized for its advanced orthobiologic therapies, particularly within the areas of pain management and equine asthma. This strategic acquisition is set to significantly enhance Creative Science's equine portfolio, broadening its spectrum of sophisticated therapeutic solutions for animal well-being. The integration of Astaria Global's specialized therapies strengthens Creative Science's capabilities in the global veterinary pain management market.
• In January 2025, Innocan Pharma Corporation was granted a sponsor fee waiver by the FDA's Center for Veterinary Medicine for its LPT-CBD drug product. This innovative subcutaneous injection is under development to manage chronic pain in dogs. The LPT-CBD platform is designed to deliver a precise and sustained release of cannabidiol from a single injection, offering a convenient and effective dosing solution for chronic pain relief in canines across various ages and sizes. This regulatory milestone represents significant progress in bringing a novel non-opioid pain management option to the global veterinary market.

Key Market Players

• Boehringer Ingelheim International GmbH
• Zoetis Inc.
• Elanco Animal Health Incorporated
• Norbrook Laboratories Limited
• SeQuent Scientific Limited
• Merck & Co., Inc.
• Dechra Pharmaceuticals Plc
• Vetoquinol S.A.
• Ceva Santé Animale SA
• Chanelle Pharma Group Ltd

By Product	By Application	By Animal Type	By Region
Medications Medical Devices	Joint Pain Cancer Pain Postoperative Pain Others	Companion Animal Livestock Animal	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Veterinary Pain Management Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Pain Management Market, By Product:

• Medications
• Medical Devices

• Veterinary Pain Management Market, By Application:

• Joint Pain
• Cancer Pain
• Postoperative Pain
• Others

• Veterinary Pain Management Market, By Animal Type:

• Companion Animal
• Livestock Animal

• Veterinary Pain Management Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE